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Mutations of CLCN5 in Japanese children with idiopathic low molec-
ular weight proteinuria, hypercalciuria and nephrocalcinosis. The annual
urinary screening of Japanese children above three years of age has
identified a progressive renal tubular disorder characterized by low
molecular weight proteinuria, hypercalciuria and nephrocalcinosis. The
disorder has been observed in over 60 patients and has a familial
predisposition. Mutations of a renal chloride channel gene, CLCN5, have
been reported in four such families, and we have undertaken studies in
additional patients from 10 unrelated, non-consanguineous Japanese
families to further characterize such CLCN5 mutations and to ascertain
their prevalence. CLCN5 abnormalities were identified in 7 of the 10
unrelated patients and consisted of 5 mutations (2 nonsense, 1 frameshift
and 2 missense), 1 deletion and 1 silent polymorphism. A clustering of
these mutations in CLCN5 exons 8 and 10 was observed. Over 80% of the
CLCN5 mutations could be readily detected by single stranded conforma-
tional polymorphism (SSCP) analysis, thereby providing a useful mutation
screening method. Our results, which indicate that over 70% of Japanese
patients with this renal tubulopathy have CLCN5 mutations, will help in
the genetic and clinical evaluation of children at risk from this disorder.
The annual urinary screening program of Japanese children
above three years of age has defined a progressive proximal renal
tubular disorder characterized by low molecular weight protein-
uria (such as /32 microglobulinuria, normal child < 320 jig/liter,
normal adult < 250 jig/liter), hypercalciuria and nephrocalcinosis
[11. Hematuria, glycosuria, aminoaciduria, an impaired urinary
concentrating ability and mild renal impairment are also associ-
ated features that may occur in some children [1—41. The disorder,
which occurs predominantly in males, has been reported to have
a familial predisposition and recent studies of four such Japanese
kindreds have demonstrated an association with mutations of the
X-linked renal chloride channel gene, CLCN5 [5]. The human
CLCN5 gene, which is located on chromosome Xpll.22, consists
of at least 12 exons that span 25 to 35 Kb of genomic DNA and
encodes a 746 amino acid protein [6, 7]. CLCN5 belongs to a
family of voltage-gated chloride channel genes (CLCNO, CLCN1
to CLCN7, and CLCNKa and CLCNKb) that encode proteins
(CLC-0, CLC-1 to CLC-7, and CLC-Ka and CLC-Kb, respec-
tively) that have about 12 transmembrane domains (Fig. 1) [6, 8,
9]. These chloride channels have an important role in the control
of membrane excitability, transepithelial transport and possibly
cell volume [8]. Heterologous expression of wild-type CLCN5 in
Xenopus oocytes has revealed that the channel, CLC-5, conducts
chloride currents that are outwardly rectifying and time-indepen-
dent [5, 10, 11], and similar expression of CLC-5 mutants that
caused this renal tubulopathy were associated with either mark-
edly reduced or absent currents [5, 10]. The CLCN5 mutations
observed in the Japanese patients were similar to those observed
in the renal tubular disorders of Dent's disease, X-linked recessive
nephrolithiasis (XRN) and X-linked recessive hypophosphatemic
rickets (XLRH) [5, 10]. Dent's disease, XRN and XLRH, which
have been described in British, North American and Italian
families, respectively, are X-linked renal proximal tubulopathies
that are characterized by low molecular weight proteinuria,
hypercalciuria, nephrocalcinosis, nephrolithiasis and renal failure
[12—161. Thus, these disorders have marked phenotypic and
genotypic similarities and we propose to refer to these variants
collectively as Dent's disease. The occurrence of the Japanese
variant, referred to as Dent'sJAPAN, has been reported in more
than 60 patients in Japan, and to date CLCN5 mutations have
been reported in four kindreds only [5]. Thus, in order to ascertain
the prevalence of CLCN5 mutations in Dent'sJAJAN, we have
undertaken investigations in 10 other Japanese kindreds, using
the combined methods of single stranded conformational poly-
morphism (SSCP) analysis and direct DNA sequence analysis [5,
10, 17].
METHODS
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Fourteen children from ten unrelated, non-consanguineous
Japanese families who were identified from the annual urinary
screening program to have /32 microglobulinuria (normal child <
320 jig/liter) were clinically and biochemically assessed for idio-
pathic low molecular weight protcinuria, hypercalciuria and
nephrocalcinosis, as previously described [1]. The details of the 14
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Fig. 1. Detection of two CLCN5 mutations in exon 8 by SSCP analysis. The results of SSCP analysis of the R347X (Lane 1) and W279X (Lane 2)
mutations (Table 2 and Fig. 2) detected in the Dent'sJAPAN families 10/95 and 20.1/95, respectively, together with three unrelated normals (Ni to N3)
are shown. The mutant bands (m), Lanes 1 and 2, differed from the wild-type (WT) bands. These SSCP results were obtained by use of CLCN5 gene
specific primers for exon 8, and 12.5% gels run at 15C and at 350 volt-hours, as previously described [5].
Table 1. Clinical and biochemical findings in 14 Dent'sJAPAN patients from 10 families
affected children from these 10 families designated 6/95, 9.2/95,
9.3/95, 10/95, 13.1/95, 15/95, 19/95, 20.1/95, 20.2/95, 21/95, are
summarized in Table 1. The clinical and biochemical details
obtained five years earlier from patient 2 of family 19/95 have
been previously reported as patient 3 [1]. Urinary samples for
assessment of 2 microglobulin were available from the mothers
of the affected children in 7 of the 10 families--13.1/95, 19/95,
9.3/95, 10/95, 9.2/95, 20.1/95 and 20.2/95 (Table 1)—and the
concentration of urinary /3 microglobulin (normal adult < 250
j.g/liter) in these mothers was 180, 2,400, 2,000, 980, 220, 1,400
and 210, respectively. Venous blood samples were obtained from
15 (14 patients in Table 1, and one mother from family 9.3/95) of
the 18 affected members (14 patients in Table 1, and the 4
mothers with 2 microglobulinuria from families 19/95, 9.3/95,
10/95 and 20.1/95) and used for mutational analysis of the CLCN5
gene [101.
DNA sequence analysis of the CLCN5 gene
DNA sequence abnormalities were initially sought for using
single stranded conformational polymorphism (SSCP) analysis.
Leukocyte DNA was extracted from the affected family members
and used with CLCN5 specific primers for PCR amplification
utilizing conditions previously described [5J. The PCR products
were analyzed for SSCPs using the Phast electrophoresis system
(Pharmacia, LKB, Uppsala, Sweden) as reported previously using
the method of silver staining with 0.025 M aqueous silver nitrate
for 10 minutes to reveal the SSCPs [5, 17]. Genomic DNA samples
from 10 unrelated normal individuals were also used as controls in
the SSCP analysis. The DNA sequence of abnormal SSCPs was
determined by the use of Taq polymerase cycle sequencing and a
semi-automated detection system (ABI 373A sequencer; Applied
Biosystems, Foster City, CA, USA) [5, 17]. In addition, these
DNA sequence abnormalities were confirmed either by restriction
endonuclease analysis of genomie PCR products obtained by use
of the appropriate primers or by sequence specific oligonucleotide
(SSO) hybridization analysis [10, 17, 18]. These DNA sequence
abnormalities were also demonstrated to be absent as common
polymorphisms in the DNA obtained from 56 unrelated normal
Japanese individuals (54 females, 2 males) and 75 unrelated
normal European individuals (40 males and 35 females). Southern
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76483
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37
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28681 130000
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30 NT
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10000 65300
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Family
Patient
13.1/95 19/95 15/95 9.3/95 10/95 9.2/95 21/95 6/95 20.1/95 20.2/95 Normal
1 2 3 4 5 6 7 8 9 10 11 12 13 14 child (adult)
Ageyears 14 13 10 ii 8 7 12 17 13 20 13 17 7 5
Sex F M M M M M M M M M M M M F
Urine
Protein
2-microglobulin p.g/liter
Occult blood
Ca/Cr %
Serum
Creatinine mg/100 ml 0.5 0.5 1.0 0.6 0.6 0.3 0.6 1.1 0.5 0.7 0.5 0.7 0.3 0.7 0.1—0.8(0.6—1.5)
ClmEq/liler 102 108 107 103 107 109 102 103 109 102 104 101 108 107 100—108
Ca mg/100 ml 10.2 9.0 9.2 9.4 10.1 9.8 9.6 9.7 9.7 9.2 9.8 9.5 10.3 9.4 9.0—10.6
P mg/100 ml 5.1 3.9 3.8 4.9 4.9 5.8 5.6 4.2 5.0 5.0 6.0 4.3 5.0 4.6 3.8—5.6
Nephrocalcinosis
Ultrasonography + + — + + NT — — — NT —
CT + + NT + + - + — — NT +
2+
129000
28
1+
65000
19
1+ 2+
45000 97000
1+
41 27
1+
20000 16000
4 11
<320(<250)
<25
Abbreviations are: Ca, calcium; Cr, creatinine; Cl, chloride; P, phosphate; CT, computerized tomography; +, present; —, absent; NT, not tested. All
values refer to those obtained on early morning samples after an overnight fast.
Glycosuriawas absent, and serum concentrations of sodium, potassium, urate and magnesium, and blood urea nitrogen were normal in all individuals.
132 microglobulinuria (> 250 .rg/liter) was present in the 4 mothers of the affected children from families 19/95, 9.3/95, 10/95 and 20.1/95.
Akuta et al: Mutation of CLCN5 gene in Japanese children 913
Table 2. CLCN5 mutations in Dent'sJAPAN families
Amino acid Restriction enzyme Detected by
Family Codon Base change (no) change change/SSO SSCP' Predicted effect
Nonsense mutations
20.1/95 279 TGG—TGA Trp—>Stop MaclIT Y
10/95 347 CGA—TGA Arg—Stop SSO Y
Missense mutations
19/95 513 GGG—GAG Gly—Glu MnlJ Y
6/95 516 CGGTGG Arg—Trp Hinfl N
Frame shift mutation
15/95 229
Y, yes; N, no
del C, ins TA 7 missense
an and
blot hybridization analysis was used to assess genomic deletions of
CLCN5 as described previously [10, 12].
RESULTS
SSCP analysis of the entire 2238 bp coding region of the
CLCN5 gene from one affected member of each of the 10
unrelated, non-consanguineous Dent'sJAPAN families (Table 1)
revealed the presence of abnormal bands (Fig. 1) in the five
families, designated 20.1/95, 10/95, 19/95, 15/95 and 20.2/95 (Table
2). In addition, PCR products could not be obtained, using any of
the CLCN5 specific primers, from the DNA of the patient from
family 9.3/95, indicating the presence of a genomic deletion of
CLCN5 in this patient. Thus, CLCN5 abnormalities were detected
by SSCP analysis in 60% of the Dent'sJAPAN families. The nature
of these SSCP abnormalities was further determined by DNA
sequence analysis, which revealed the presence of four mutations
that consisted of two nonsense (W279X, R347X), 1 missense
(G513E) and I insertional-deletional mutation resulting in a
frameshift (229fs) mutation, and one silent polymorphism
(T484T) (Table 2 and Fig. 2). In addition, DNA sequence analysis
of the entire 2238 bp coding region of the CLCN5 gene was
performed in the patients from the four families (6/95, 9.2/95,
13.1/95 and 21/95) in whom SSCP abnormalities were not de-
tected. This revealed the presence of one additional missense
mutation (R516W) (Fig. 3) that had not been detected by SSCP
analysis (Table 2). Thus, CLCN5 abnormalities consisting of 5
mutations, 1 deletion and I polymorphism (Table 2 and Fig. 2)
were detected in 70% of the 10 Dent'sJAPAN families. Two of
these mutations (W279X and R347X) from families 20.1/95 and
11)195, respectively, occurred in exon 8; another two mutations
(G5I3E and R516W) occurred in exon 10, which encodes the
putative transmembrane domain 11 (Dli) (Fig. 2). One mutation
(229fs) occurred in exon 6 and the polymorphism (T484T)
occurred in exon 9. The W279X mutation resulted from a G to A
transition (TGG—sTGA), the R347X resulted from a C to T
transition (CGA—+TGA), the G513E mutation resulted from a G
to A transition (CGG—GAG), the R516W mutation resulted
from a C to T transition (CGG—TGG), the 229fs mutation
resulted from a deletion of one base pair (C) and an insertion of
two base pairs (TA), and the polymorphism T484T resulted from
a C to T transition (ACC—ACT). The W279X, G513E and
R516X mutations, and the T484T polymorphism resulted in an
alteration of a restriction enzyme site (Table 2) that facilitated its
detection and confirmation (Fig. 3). The R347X and 229fs
mutations were not associated with an altered restriction enzyme
site and the method of sequence specific oligonucleotide (SSO)
hybridization was used to facilitate their detection and confirma-
tion (Table 2). The extent of the CLCN5 deletion in the affected
members of family 9.3/95 was assessed by Southern blot hybrid-
ization analysis and PCR using the genetic markers L(F1001),
DXS255 (M2713), DXSI46 and DXS988 [6, 12]. The loci DXS255
(M2713) and L(F1001), which are within a 180Kb region [6], were
deleted whereas the loci DXS146 and DXS988, which are more
than 2 Mbp in the telomeric and centromeric directions, were
present (data not shown). Thus, the genomic deletion in family
9.3/95 encompassed CLCN5, DXS2SS (M27) and L(F1001) and
indicated that this deletion was greater than 180 Kb in size. The
absence of each of these 7 DNA sequence abnormalities (5
mutations, 1 deletion and 1 polymorphism) in 220 alleles from 130
unrelated normal individuals (56 Japanese and 75 Northern
Europeans) established that these abnormalities were not com-
mon sequence polymorphisms that would be expected to occur in
>1% of the population.
DISCUSSION
Our results, which have identified 5 mutations, I deletion, and
1 silent polymorphism of the CLCN5 gene in Japanese families
with low molecular weight proteinuria, hypercalciuria and
nephroealcinosis (Dent's JAPAN)' expand the spectrum of such
mutations associated with this proximal renal tubulopathy. Each
of the five mutations (229 fs, W279X, R347X, G513E and
R516W) and the CLCN5 deletion predicts a structurally signifi-
cant alteration to CLC-5 (Table 2 and Fig. 2) and is thus likely to
be of importance in the etiology of the disease. The two nonsense
mutations (W279X and R347X), and the frameshift mutation that
results in a termination at codon 235, predict truncated CLC-5
channels that lack respectively the 469 amino acids from 1)6 to the
C-terminus, the 399 amino acids from D8 to the C-terminus, and
the 510 amino acids from D5 to the C-terminus. The effects upon
CLC-5 function of such nonsense mutations, which have been
previously assessed [101, are likely to be a loss of function. The two
Deletion
9.3/95
Polymorphism
20.2/95
stop
484
sso Y
Loss of 469 amino acids from D6 to C terminus
Loss of 399 amino from D8 to C terminus
Disruption of charge distribution within Dii
Disruption of charge distribution within Dli
Missense peptide from amino acids 229-235 and
loss of 510 amino acids from D5 to C
terminus
>180 kb deletion Absence of protein
ACC—ACT No change AvaIl Y No change
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Fig. 2. Schematic representation of the Dent'sJAPAN mutations within the framework of the predicted topology of CLC-5, which consists of 746 amino
acids [6, 10). The correct topology of the CLC-5 putative transmembrane domains (Dl to D13) is based upon a model [8, 10, 191 (inset) that places
D4 extracellularly, and in which the hydrophobic core of the D9 - Dl2 crosses the membrane 3 or 5 times and contains a hydrophilic region whose precise
location remains unkown. The consensus phosphorylation and glycosylation sites are indicated by asterisks and branch signs, respectively. The four
previously reported CLCN5 mutations (W279X, R280P, W343X and 7695:Cdel) [51 in Dent'sJAPAN patients and the 5 additional CLCN5 mutations
(R347X, W279X, G513E, R516W and the deletional—insertional frameshift mutation at codon 229 (del C, ins TA) detected by the present study are
shown. The location of a silent polymorphism at T484T, which is unlikely to alter CLC-5 function as it is not associated with an altered amino acid in
the channel, is also illustrated. In addition to these 9 mutations and one polymorphism, a microdeletion (Table 2) that was > 180 Kb in size and which
encompassed the entire CLCN5 gene was found in one Dent'sJAPAN family (9.3/95, Table 1). Thus, of the 14 Dent'sJAPAN families studied to date,
functionally significant CLCN5 abnormalities have been identified in 10, representing > 70%, of the kindreds.
missense mutations (G513E and R516W) also predict significant
changes to CLC-5. Thus, the mutation of codon 513 results in the
replacement of an uncharged amino acid (glycine, G) for a
negatively charged amino acid (glutamate, E), thereby leading to
a disruption of charge distribution within the putative transmem-
brarie domain Dli (Fig. 2). Similarly, the mutation of codon 516
results in the replacement of a charged amino acid (arginine, R)
for an uncharged, non-polar, hydrophobic amino acid (trypto-
phan, W), and this again is likely to lead to a disruption of charge
distribution within DII (Fig. 2). The effects of such missense
mutations involving the highly conserved Dli [6], for example
G506E, G512R and S520P, upon CLC-5 electrophysiological
function, using the Xenopus oocyte expression system, have been
previously demonstrated to result in either a complete loss or a
marked reduction in the biological activity of CLC-5 [10, 19, 20].
It is thus highly probable that the in vitro electrophysiological
effects of the disease-causing (that is, in vivo effects) mutations
G513E and R5I6W would be similar, and such in vilro studies of
the mutant CLC-5 genes were therefore not undertaken. A
correlation between the different mutations (Table 2 and Fig. 2)
and the severity of the phenotype (Table 1) could not be
established, and the patients with the nonsense mutations, the
missense mutations, and those in whom CLCN5 mutations were
not identified, all had similar phenotypes (Tables I and 2). In
addition, the increased variability of the phenotype in females
which ranged from isolated /32 microglobulinuria to the additional
presence of hypercalciuria and nephrocalcinosis (such as patient I
in Table 1) has been previously observed [10, 12, 13, 211 and is
likely to result from the variability of X chromosome inactivation
observed in females [13, 21]. The absence of CLCN5 mutations in
families 9.2/95, 13.1/95, 20.2/95 and 25/95 (Table 1) may either be
because these patients have another form of Dent'sJAPAN or that
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human kidney will represent an important step in elucidating such
possibilities.
The CLCN5 mutations appear to cluster in three regions.
Firstly, 5 of the 10 mutations identified to date from the present
and previous studies [5] of Dent'sJAI,AN families occur in exon 8
which encodes codons 269 to 449 [TI. Secondly, the W279X
mutation, resulting from TGG—sTGA, has been observed to
occur in three unrelated families (2 Japanese and 1 British) [5,
101, and this represents a possible mutational hot-spot. Thirdly,
transmembrane domain Dli, which is highly conserved in other
CLC members (> 95% identity between CLC-3, CLC-4 and
CLC-5) [6] and is encoded by part of exon 10, has been observed
to harbor 5 of the 26 reported mutations [5, 10, 201. These results
indicate that a possible useful strategy to investigate for CLCN5
mutations might be to first investigate exons 8 and 10 for
mutations. Such mutational analysis may initially be undertaken
by SSCP, which has detected over 80% of the 26 reported CLCN5
mutations (6 from the present study and 20 previously reported)
[5, 10, 201. Two of the Dent'sJAPAN mutations (R347X and
R516W) and three of the previously reported mutations (S244L,
R648X and R704X) [10] involved a C to T transition that occurred
at a CpG site, which is the most common site of methylation in
mammalian DNA [22]. Such sites have been previously reported
WT to represent potential "hot spots" for mutations as deamination of
the 5-methylcytosine results in a C to T transition [23]. Our results
m revealing over 20% of CLCN5 mutations at such sites are
consistent with these observations. In addition, our results indi-
cate that CLCN5 mutations can be detected in over 70% of
Dent'sJAPAN patients and that over 80% of these mutations can be
readily investigated for by SSCP. Thus, the results of our study will
help in the genetic and clinical evaluation of patients at risk from
Dent'sJAPAN and other such similar X-linked renal proximal
tubulopathies.
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